A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

NCT07710690 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

HGG
High Grade Glioma (III or IV)
High Grade Glioma

Interventions

DRUG: NRG-103

Sponsor

Neuregen Therapeutics Co., Ltd.